Xinruibai is the trade name and the generic name of the drug is Polyethylene Glycolized Recombinant Human Granulocyte Stimulating Factor Injection, which works to promote the production of leukocytes and acts to reduce the incidence of infections caused by neutropenia. The mechanism of action of Polyethylene Glycolized Recombinant Human Granulocyte Stimulating Factor Injection is that the granulocyte stimulating factor binds to the surface receptor of hematopoietic cells, thus stimulating the production of leukocytes. It is mostly used clinically in patients with non-myeloid malignancies receiving antineoplastic agents to reduce the incidence of febrile neutropenia-induced infections when febrile neutropenic myelosuppression is likely to occur. It should be noted that this drug is not used for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. In addition, the use of polyethylene glycolized recombinant human granulocyte stimulating factor injection is contraindicated in people who are allergic to any component of this drug, as well as in people with severe hepatic, renal, cardiac or pulmonary dysfunction. Some patients may experience adverse reactions such as bone pain, arthralgia, fatigue, palpitation, insomnia, fever, dizziness, etc., and in severe cases, splenic rupture, acute respiratory distress syndrome and other discomforts, and it is recommended to inform the doctor in time so as to deal with them accordingly. Polyethylene glycolized recombinant human granulocyte stimulating factor injection should be used by professional doctors, patients should not self-medication, so as not to affect the condition, or induce adverse reactions.